November 24, 2021
November 24, 2021 —
The California Institute for Regenerative Medicine (CIRM) approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.
November 24, 2021
November 24, 2021 —
Artificial intelligence-based technique reveals previously unknown cell components that may provide new clues to human development and disease.
July 12, 2021
July 12, 2021 —
UC San Diego researchers discovered that immunotoxins targeting the protein mesothelin prevent liver cells from producing collagen, a precursor to fibrosis and cirrhosis, in mouse models of human disease.
June 17, 2021
June 17, 2021 —
UC San Diego School of Medicine researchers discovered that the enzyme RNA polymerase II recognizes and transcribes artificially added base pairs in genetic code, a new insight that could help advance the development of new vaccines and medicines.
December 8, 2020
December 8, 2020 —
Compared to chimpanzees, our closest evolutionary cousins, humans are particularly prone to developing advanced carcinomas — the type of tumors that include prostate, breast, lung and colorectal cancers — even in the absence of known risk factors, such as genetic predisposition or tobacco use.
October 22, 2020
October 22, 2020 —
UC San Diego researchers use experimental artificial intelligence system called DrugCell to predict the best approach to treating cancer. Only 4 percent of all cancer therapeutic drugs under development earn final approval by the U.S. Food and Drug Administration (FDA).
August 17, 2020
August 17, 2020 —
UC San Diego researchers discovered that tumor cells in younger and female patients accumulate cancer-causing mutations that are more poorly presented to the immune system, better enabling tumors to escape detection and clearance.
April 11, 2019
April 11, 2019 —
Treatment with a choline kinase inhibitor prompts immune cells to clear away damaged mitochondria, thus reducing NLRP3 inflammasome activation and preventing inflammation
April 11, 2019
April 11, 2019 —
Treatment with a choline kinase inhibitor prompts immune cells to clear away damaged mitochondria, thus reducing NLRP3 inflammasome activation and preventing inflammation
July 5, 2018
July 5, 2018 —
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego have found that the cost for the 10 “highest spend” medications in Medicare Part D — the U.S. federal government’s primary prescription drug benefit for older citizens — rose almost one-third between 2011 and 2015, even as the number of persons using these drugs dropped by the same amount.
